JP2024520674A5 - - Google Patents
Info
- Publication number
- JP2024520674A5 JP2024520674A5 JP2023574472A JP2023574472A JP2024520674A5 JP 2024520674 A5 JP2024520674 A5 JP 2024520674A5 JP 2023574472 A JP2023574472 A JP 2023574472A JP 2023574472 A JP2023574472 A JP 2023574472A JP 2024520674 A5 JP2024520674 A5 JP 2024520674A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- ch2ch2o
- iii
- pharmaceutically acceptable
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021098024 | 2021-06-02 | ||
| CNPCT/CN2021/098024 | 2021-06-02 | ||
| CN202110651300 | 2021-06-10 | ||
| CN202110651300.6 | 2021-06-10 | ||
| CN202111198590.X | 2021-10-14 | ||
| CN202111198590 | 2021-10-14 | ||
| CN202111595515.7 | 2021-12-23 | ||
| CN202111595515 | 2021-12-23 | ||
| CN202111602429 | 2021-12-24 | ||
| CN202111602429.4 | 2021-12-24 | ||
| PCT/CN2022/096690 WO2022253284A1 (zh) | 2021-06-02 | 2022-06-01 | 药物偶联物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520674A JP2024520674A (ja) | 2024-05-24 |
| JP2024520674A5 true JP2024520674A5 (cg-RX-API-DMAC7.html) | 2025-06-06 |
Family
ID=84240734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574472A Pending JP2024520674A (ja) | 2021-06-02 | 2022-06-01 | 薬物コンジュゲート及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240269315A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4349371A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024520674A (cg-RX-API-DMAC7.html) |
| CN (2) | CN117295524A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022253284A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4273167A4 (en) * | 2020-12-30 | 2025-03-26 | Bio-Thera Solutions, Ltd. | ANTI-CLDN18.2 ANTIBODIES AND PRODUCTION METHOD AND USE THEREOF |
| US20250262316A1 (en) * | 2021-10-14 | 2025-08-21 | Bio-Thera Solutions, Ltd. | Antibody-drug conjugate and application thereof |
| US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| CN116333135A (zh) * | 2021-12-24 | 2023-06-27 | 百奥泰生物制药股份有限公司 | 抗FRα抗体及其抗体药物偶联物和用途 |
| EP4509141A4 (en) * | 2022-04-12 | 2026-08-19 | Bio Thera Solutions Ltd | TREATMENT METHOD FOR A HER2-POSITIVE SOLID TUMOR |
| WO2023232080A1 (zh) * | 2022-06-01 | 2023-12-07 | 百奥泰生物制药股份有限公司 | 抗cldn18.2抗体及其抗体药物偶联物和用途 |
| CN119421724A (zh) * | 2022-06-27 | 2025-02-11 | 百奥泰生物制药股份有限公司 | 治疗实体瘤的方法 |
| CN117982672A (zh) * | 2022-07-14 | 2024-05-07 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体药物偶联物及应用 |
| WO2024012566A2 (en) | 2022-07-15 | 2024-01-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody, linkers, payload, conjugates and applications thereof |
| EP4650355A1 (en) * | 2023-01-09 | 2025-11-19 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Preparation method for nitrogen-containing fused ring compound |
| KR20250152646A (ko) * | 2023-03-01 | 2025-10-23 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 인데노[1,2-b]퀴놀린-10,13-디온 유도체의 제조 방법 |
| WO2025002310A1 (zh) * | 2023-06-29 | 2025-01-02 | 石药集团巨石生物制药有限公司 | 抗体-药物偶联物及其用途 |
| CN121772942A (zh) * | 2023-08-11 | 2026-03-31 | 百奥泰生物制药股份有限公司 | 抗FRα抗体药物偶联物在治疗疾病中的应用 |
| AU2024369355A1 (en) * | 2023-10-23 | 2026-05-07 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Camptothecin drug conjugate, and preparation method therefor and use thereof |
| AU2024380559A1 (en) | 2023-11-17 | 2026-06-04 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2025153092A1 (en) * | 2024-01-18 | 2025-07-24 | Beijing Joinn Biologics Co., Ltd | Antibody-drug conjugate |
| WO2025190255A1 (zh) * | 2024-03-12 | 2025-09-18 | 百奥泰生物制药股份有限公司 | 治疗宫颈癌、胸腺肿瘤或激素受体阳性和her2阴性乳腺癌的方法 |
| WO2025190251A1 (zh) * | 2024-03-12 | 2025-09-18 | 百奥泰生物制药股份有限公司 | 抗trop2抗体药物偶联物和pd-1拮抗剂联合治疗实体瘤的用途 |
| WO2025190318A1 (zh) * | 2024-03-13 | 2025-09-18 | 百奥泰生物制药股份有限公司 | 抗her2抗体药物偶联物和her二聚化抑制剂联合治疗实体瘤 |
| CN120837674A (zh) * | 2024-04-28 | 2025-10-28 | 百奥泰生物制药股份有限公司 | 抗Nectin-4抗体药物偶联物治疗肿瘤的方法 |
| CN120919340A (zh) * | 2024-05-09 | 2025-11-11 | 百奥泰生物制药股份有限公司 | 抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用 |
| CN121015903A (zh) * | 2024-05-27 | 2025-11-28 | 百奥泰生物制药股份有限公司 | 抗trop2抗体药物偶联物和vegf-a抑制剂联合治疗肿瘤的用途 |
| CN121015902A (zh) * | 2024-05-27 | 2025-11-28 | 百奥泰生物制药股份有限公司 | 抗trop2抗体药物偶联物和抗pd-l1/cd47双特异抗体联合治疗肿瘤的用途 |
| WO2026002234A1 (zh) * | 2024-06-29 | 2026-01-02 | 百奥泰生物制药股份有限公司 | 药物偶联物及其制备方法和用途 |
| CN121606577A (zh) * | 2024-08-27 | 2026-03-06 | 百奥泰生物制药股份有限公司 | 抗FRα抗体药物偶联物和VEGF拮抗剂在治疗肿瘤中的应用 |
| WO2026108920A1 (zh) * | 2024-11-20 | 2026-05-28 | 江苏恒瑞医药股份有限公司 | 配体-药物偶联物及其医药用途 |
| WO2026151884A1 (en) | 2025-01-09 | 2026-07-16 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2235269C (en) | 1995-10-19 | 2006-09-19 | Bristol-Myers Squibb Company | Monoclonal antibody br110 and uses thereof |
| CA2478047C (en) | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EA201500220A1 (ru) | 2010-05-17 | 2015-10-30 | Ливтех, Инк. | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo |
| WO2011155579A1 (ja) | 2010-06-10 | 2011-12-15 | 北海道公立大学法人札幌医科大学 | 抗Trop-2抗体 |
| SG11201401699WA (en) | 2011-11-11 | 2014-09-26 | Rinat Neuroscience Corp | Antibodies specific for trop-2 and their uses |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| PT3057585T (pt) * | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
| SG10201902571VA (en) | 2013-12-25 | 2019-04-29 | Daiichi Sankyo Co Ltd | Anti-trop2 antibody-drug conjugate |
| MY199595A (en) * | 2016-03-02 | 2023-11-08 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
| US20210093733A1 (en) * | 2016-11-21 | 2021-04-01 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| CN111936169A (zh) * | 2018-04-06 | 2020-11-13 | 西雅图遗传学公司 | 喜树碱肽缀合物 |
| WO2019243825A1 (en) * | 2018-06-21 | 2019-12-26 | Curadev Pharma Limited | Small molecule modulators of human sting, conjugates and therapeutic applications |
| CN110862454B (zh) | 2018-08-27 | 2022-12-30 | 南京圣和药业股份有限公司 | 一种抗Claudin18_2抗体及其应用 |
| CN110903395A (zh) | 2018-09-14 | 2020-03-24 | 四川科伦博泰生物医药股份有限公司 | 抗体、偶联物及其制备方法和用途 |
| JP7401538B2 (ja) | 2018-10-22 | 2023-12-19 | シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド | 抗cldn18.2抗体およびその使用 |
| EP3876998A1 (en) * | 2018-11-05 | 2021-09-15 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| CA3140063A1 (en) * | 2019-05-20 | 2020-11-26 | Novartis Ag | Antibody drug conjugates having linkers comprising hydrophilic groups |
| CA3085001C (en) * | 2019-05-20 | 2021-10-05 | Mabplex International, Ltd. | One-pot process for preparing intermediate of antibody-drug conjugate |
| JP7641967B2 (ja) | 2019-12-06 | 2025-03-07 | ソティオ バイオテック エイ.エス. | ヒト化cldn18.2抗体 |
| US20230101735A1 (en) | 2020-01-22 | 2023-03-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof |
| US20230312704A1 (en) | 2020-02-10 | 2023-10-05 | Shanghai Escugen Biotechnology Co., Ltd. | Cldn18.2 antibody and use thereof |
| WO2021238831A1 (en) | 2020-05-25 | 2021-12-02 | Mabspace Biosciences (Suzhou) Co., Limited | Anti-cldn18.2 antibodies and diagnostic uses thereof |
| CN116589587A (zh) | 2020-06-22 | 2023-08-15 | 四川百利药业有限责任公司 | 一种抗trop2抗体 |
-
2022
- 2022-06-01 EP EP22815326.8A patent/EP4349371A4/en active Pending
- 2022-06-01 JP JP2023574472A patent/JP2024520674A/ja active Pending
- 2022-06-01 CN CN202280032877.1A patent/CN117295524A/zh active Pending
- 2022-06-01 US US18/566,371 patent/US20240269315A1/en active Pending
- 2022-06-01 WO PCT/CN2022/096690 patent/WO2022253284A1/zh not_active Ceased
- 2022-06-01 CN CN202210617443.XA patent/CN115429893A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024547111A5 (cg-RX-API-DMAC7.html) | ||
| AU2018267660B2 (en) | Compounds and methods for the treatment of TROP2 positive diseases | |
| CN103269712B (zh) | 包含新型安丝菌素衍生物的细胞毒性剂 | |
| RU2523419C2 (ru) | Конъюгаты производного антрациклина, способы их получения и их применение в качестве противоопухолевых соединений | |
| US8841425B2 (en) | Cytotoxic agents comprising new maytansinoids | |
| CN103333246B (zh) | 一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途 | |
| CN103288957B (zh) | 一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途 | |
| HRP20130953T1 (hr) | Pirolobenzodiazepini i njihovi konjugati | |
| US20250249114A1 (en) | Method for treating her2-positive solid tumor | |
| CN1816356A (zh) | 药物缀合物组合物 | |
| CA2525130A1 (en) | Improved cytotoxic agents comprising new maytansinoids | |
| CN102731611A (zh) | 细霉素衍生物 | |
| CN119421724A (zh) | 治疗实体瘤的方法 | |
| Hamann | Monoclonal antibody–drug conjugates | |
| WO2025190255A1 (zh) | 治疗宫颈癌、胸腺肿瘤或激素受体阳性和her2阴性乳腺癌的方法 | |
| CN120837674A (zh) | 抗Nectin-4抗体药物偶联物治疗肿瘤的方法 | |
| CN119454999A (zh) | 抗FRα抗体药物偶联物在治疗疾病中的应用 | |
| CN119899238A (zh) | 稠环化合物及其制备方法和用途 | |
| HK1092730A (en) | Drug conjugate composition |